Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865 is registered in ClinicalTrials.gov with COMPASS Pathways as lead sponsor.

NCT NCT04739865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Lead sponsor
COMPASS Pathways
Phase
Phase 2
Overall status
Completed
Start date
August 10, 2020
Completion date
October 14, 2021
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression